Format

Send to

Choose Destination
BMC Nephrol. 2019 May 14;20(1):169. doi: 10.1186/s12882-019-1355-5.

Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries.

Author information

1
Arbor Research Collaborative for Health, Ann Arbor, MI, USA. Doug.Fuller@ArborResearch.org.
2
Amgen, Inc., Thousand Oaks, CA, USA.
3
Amgen (Europe) GmbH, Rotkreuz, Switzerland.
4
Cliniques Universitaires St-Luc, Université catholique de Louvain, Bruxelles, Belgium.
5
Departments of Epidemiology and Environmental Health Sciences, School of Public Health, and Department of Urology, Medical School, University of Michigan, Ann Arbor, MI, USA.
6
Arbor Research Collaborative for Health, Ann Arbor, MI, USA.
7
DaVita, Inc., Minneapolis, MN, USA.
8
Vanderbilt University School of Medicine, Nashville, TN, USA.

Abstract

BACKGROUND:

The putative benefits of cinacalcet therapy for management of secondary hyperparathyroidism (SHPT) are thought to be most manifested when patients are taking it consistently and as prescribed. Real-world descriptions of cinacalcet prescription discontinuation and reinitiation in European hemodialysis patients are lacking. To address this knowledge gap, we used Dialysis Outcomes and Practice Patterns Study (DOPPS) data, based on dialysis facility medical records, from seven European countries to estimate rates and predictors of cinacalcet prescription discontinuation and reinitiation in hemodialysis patients and to describe the trajectories of CKD-MBD laboratory values after discontinuation.

METHODS:

Cox regression analyses were used to predict (1) cinacalcet discontinuation among 613 patients with ≥3 consecutive months without cinacalcet prescription immediately prior to a new cinacalcet prescription and (2) cinacalcet reinitiation among 415 patients with a newly discontinued cinacalcet prescription immediately after ≥3 consecutive months of prescribed use.

RESULTS:

Cinacalcet was discontinued in 21 and 35% of new users after 6 and 12 months, respectively. Cinacalcet was reinitiated in 38 and 49% of newly-discontinued users after 6 and 12 months, respectively. Predictors of discontinuation included lower parathyroid hormone (PTH) in the previous month (< 150 pg/ml vs. 150-299, HR = 2.57 [95% CI: 1.52-4.33]) and lower serum calcium in the previous month (< 8.4 mg/dl vs. 8.4-10.19, HR = 1.67 [95% CI: 1.08-2.59]). Predictors of reinitiation included higher PTH in the previous month (300-599 pg/ml vs. 150-299, HR = 1.88 [95% CI = 1.19-2.97]; 600+ pg/ml, HR = 3.02 [95% CI = 1.92-4.76]). After cinacalcet discontinuation, mean serum PTH increased from 408 to 510 pg/ml, mean serum calcium briefly rose from 9.12 to 9.22 mg/dl before declining to 9.06 mg/dl, and mean serum phosphorus showed little change.

CONCLUSIONS:

Nephrologist discontinuation of cinacalcet therapy is common in European countries. Additional research is needed to identify optimal cinacalcet treatment strategies for SHPT management, including comparisons of intermittent cinacalcet therapy versus sustained treatment with reduced dose or frequency.

KEYWORDS:

Cinacalcet; Hemodialysis; Parathyroid hormone

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center